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Abstract
Background: Highly active antiretroviral treatment (HAART) programs have been associated with declines in the burden of
invasive pneumococcal disease (IPD) in industrialized countries. The aim of this study was to evaluate trends in IPD
hospitalizations in HIV-infected adults in Soweto, South Africa, associated with up-scaling of the HAART program from 2003
to 2008.
Methods: Laboratory-confirmed IPD cases were identified from 2003 through 2008 through an existing surveillance
program. The period 2003-04 was designated as the early-HAART era, 2005–06 as the intermediate-HAART era and 2007–08
as the established-HAART era. The incidence of IPD was compared between the early-HAART and established-HAART eras in
HIV-infected and–uninfected individuals.
Results: A total of 2,567 IPD cases among individuals older than 18 years were reported from 2003 through 2008. Overall
incidence of IPD (per 100,000) did not change during the study period in HIV-infected adults (207.4 cases in the early-HAART
and 214.0 cases in the established-HAART era; p=0.55). IPD incidence, actually increased 1.16-fold (95% CI: 1.01; 1.62) in
HIV-infected females between the early-and established-HAART eras (212.1 cases and 246.2 cases, respectively; p=0.03). The
incidence of IPD remained unchanged in HIV-uninfected adults across the three time periods.
Conclusion: Despite a stable prevalence of HIV and the increased roll-out of HAART for treatment of AIDS patients in our
setting, the burden of IPD has not decreased among HIV-infected adults. The study indicates a need for ongoing monitoring
of disease and HAART program effectiveness to reduce opportunistic infections in African adults with HIV/AIDS, as well as
the need to consider alternate strategies including pneumococcal conjugate vaccine immunization for the prevention of
IPD in HIV-infected adults.
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Introduction
HIV-infected adults in the absence of highly active antiretroviral
treatment (HAART) have an increased risk of developing invasive
disease from Streptococcus pneumoniae (IPD) and are at heightened
susceptibility of recurrent IPD episodes. [1,2,3,4] The initiation of
HAART in many developed countries since the mid-1990s has
been associated with marked reductions in morbidity and
mortality from opportunistic infections due to humoral and cell-
mediated immune reconstitution with HAART. [5] Protection
against IPD is dependent upon opsonisation of the pneumococcus
by antibodies and subsequent killing thereof by phagocytic activity.
Two- to three-fold reductions in the risk of IPD have been
observed among HIV-infected adults developed country settings
where HAART programs have been effectively implemented.
[6,7,8] Nevertheless, in the United States the incidence of IPD in
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27929HIV-infected adults in the era of HAART continued to be
approximately 35-fold greater than the general population. [7]
The widespread use of HAART in industrializing countries has
lagged behind that in developed countries so that the impact
thereof on the burden of opportunistic infections remains to be
fully quantified. Only a few studies have been published to date
from Africa, the continent with the highest prevalence and
number of individuals with HIV/AIDS, suggesting a reduction in
opportunistic infections incidence with HAART usage. [9,10]
Following global initiatives for the up-scaling of HAART access
for HIV-infected individuals in industrializing countries since
2003, South Africa embarked on a national program of HAART
management in 2004. [11] The estimated prevalence of HIV
among African adults aged 18–64 years was 25% in 2004 and
27% in 2008 in the province of Gauteng, South Africa, where this
study was undertaken. [12,13,14] Previous studies on the impact of
HIV/AIDS on IPD in adults in South Africa were undertaken
prior to the HAART era. [2,15,16] Determination of the impact of
HAART on the burden of IPD in African settings is necessary to
determine whether the prevention of IPD in African HIV-infected
individuals remains a priority.
The aim of this study was to evaluate the impact of the HAART
program on the burden of hospitalization for IPD in South African
HIV-infected adults.
Methods
Study design and study population
The analysis included all laboratory-confirmed IPD episodes
hospitalized at Chris Hani-Baragwanath Hospital (CHBH) from
January 2003 to December 2008. CHBH is a public hospital,
providing curative health-care to approximately 1.4 million
African urban South Africans living in Soweto. [17] Approxi-
mately 18% of the Sowetan population has private medical
insurance and may attend private hospitals, whilst the remainder
of the population among whom unemployment rate is 25% are
primarily admitted to CHBH when requiring hospitalization. [17]
Neither pneumococcal polysaccharide vaccine (PPV23) immuni-
zation of HIV-infected adults nor pneumococcal conjugate
vaccine (PCV) immunization of children was available as
standard-of-care during the period reviewed.
The analysis was divided into 3 eras according to the national
estimates of HAART coverage of adults with AIDS. [18] The
numerators for era-specific disease incidences were the numbers of
IPD episodes hospitalized during each era, and the population
denominator was based on the Gauteng Department of Health
and Social Development, Statistics South Africa, population
estimates for Region D (i.e. Soweto) in Johannesburg, South
Africa. [17] HIV prevalence in the study population was estimated
from the 2010 projections of the AIDS and Demographic model
developed by the Actuarial Society of South Africa. [14] These
estimates have been shown to correlate with estimates from
population-based studies. [13] Exact figures of the number of HIV
infected individuals requiring HAART treatment are difficult to
estimate due to uncertainty about the number who fulfil the
eligibility criteria for treatment. South African Department of
Health criteria for HAART initiation in adolescents and adults
during the period under review were: CD4+ T lymphocyte
(CD4+) cell count less than 200 cells per microliter; or World
Health Organization (WHO) stage IV irrespective of CD4+ cell
count. [19] Considering these criteria and the prevalence of HIV/
AIDS, the national estimates of antiretroviral coverage at mid-year
were 3.0% in 2003, 4.9% in 2004, 10.0% in 2005, 19.7% in 2006,
28.3% in 2007 and 40.2% in 2008 [18]. We designated the initial
period of 2003–04 as the early-HAART era, the period 2005–06
as the intermediate-HAART era and 2007–08 was categorized as
the established-HAART era.
Invasive pneumococcal disease surveillance
An IPD episode was defined as identification of pneumococcus
from a normally sterile site (e.g., cerebrospinal fluid [CSF], blood,
pleural fluid or joint fluid). Repeat IPD episodes from the same
individual more than 21 days apart were considered as new
episodes. The standard culture methods at the hospital included
blood and CSF cultured for pneumococcal growth with the BacT/
Alert microbial detection system (Organon Teknika, Durham,
NC). Autolysed blood culture specimens, macroscopically choco-
late-coloured with or without pleomorphic Gram-positive cocci on
microscopy, were tested with latex agglutination kit (Wellcogen
Bacterial Antigen Kit, Remel Europe Ltd, Dartford, UK). As a
quality control, blood cultures positive for pneumococcal antigen
were confirmed by pneumococcal surface adhesin A (PsaA) PCR
during 2004, and from January 2007 onwards at the surveillance
reference laboratory. [20] A 99.7% (332/333) concordance was
identified between the PCR and latex-agglutination test. [21]
Peritoneal, pericardial and other fluid samples were processed
according to standard culture procedures. [22]
IPD episodes were categorized as: i) ‘‘pneumococcal meningi-
tis’’: if pneumococci were cultured from CSF; if the latex antigen
detection was positive on CSF; or when the CSF white cell count
and/or biochemistry was suggestive of purulent meningitis with
pneumococci isolated from blood; ii) ‘‘pneumococcal non-
meningitis cases’’: if pneumococci were detected from blood,
pleural fluid or from sterile sites other than CSF in the absence of
clinical or laboratory diagnosis of meningitis.
IPD episodes were recorded through a surveillance system
under the auspices of the National Institute for Communicable
Diseases (NICD), [23] and included prospective collection of
clinical and demographic data. Audits comparing cases recorded
by the NICD surveillance system against the hospital’s electronic
laboratory database ensured record completeness of identification
of all IPD episodes. Audits revealed that 99.0%, 93.6% and 92.4%
of the IPD episodes in the early-, intermediate- and established-
HAART eras, respectively, had been recorded by the NICD
surveillance program. Cases not reported to the NICD, and
identified through the hospital electronic database, were included
in the final database following retrospective review of demographic
characteristics.
Determination of HIV infection status
HIV infection status was based on HIV testing done as
standard-of-care by attending physicians. This was performed
using HIV enzyme-linked immunosorbent assay (ELISA). For the
primary analysis of IPD incidence, we inferred the HIV status in
patients not tested for HIV by assuming that the prevalence of
HIV infection was the same as for those who were tested, stratified
by each of the three individual study periods. In a parallel analysis
we calculated IPD incidences on individuals with confirmed HIV
infection status. CD4+ cell counts taken within 3 months of the
IPD episode were categorized into four groups: 0–100, 101–200,
201–350 and .350 cells per microliter.
Estimation of HAART effectiveness
The screening method, based on the comparison of the
proportion of cases with CD4+ cell count #200 cells per
microliter on HAART and the proportion on HAART in the
population, was used to estimate the effectiveness of HAART in
the study population, using the formula: [24]
High IPD Burden in the HAART Era
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Statistical analysis
Estimated incidence of IPD was calculated for the three HAART-
eras stratified by age, gender and HIV status to yield stratum-specific
incidence rates. Age groups were: 18–24 years-old, 25–44 years-old,
45–64 years-old and $65 years-old. Incidence risk ratios (IRR) were
calculated by comparing group-specific incidence for the established-
and early-HAART eras. Mortality was assessed as case-fatality ratio
(CFR) (proportion of cases with known outcome who died during
their hospitalization) and incidence of IPD-associated death.
Chi-square test and Fisher’s exact test when necessary were used
to compare the distribution of categorical variables. 95%
confidence intervals (CIs) are reported and p-values ,0.05 were
considered statistically significant. Continuous variables were
compared using analysis of variance. Poisson regression was used
to calculate CFR comparing patients with different CD4+ cell
counts and 95% CIs adjusted for diagnosis. Demographic data
and estimates of incidence and risk ratio were analysed using
STATA version 11.0 (College Station, Texas, USA) and Epi Info
3.5.1 (CDC, Atlanta, Georgia, USA).
Ethics
The surveillance study and site-specific analysis were approved
by the Human Research Ethics Committee (Medical), from the
University of the Witwatersrand, South Africa (protocol numbers
M081117 and M090663, respectively). The overall surveillance
approval is reviewed annually and includes getting written
informed consent from all patients interviewed as part of the
surveillance. On the cases detected through the regular retrospec-
tive audits no informed consent was required.
Results
Overall, 2,567 IPD cases were identified from 2003 to 2008.
This included 772 episodes during the early-HAART era, 900 in
the intermediate-HAART era and 895 during the established-
Table 1. Baseline demographic and clinical features of adults with invasive pneumococcal disease during different periods of the
HAART program.
Early-HAART era
Intermediate-HAART
era
Established -HAART
era p=
6-year period
(2003–2008)
Total isolates 772 900 895 2,567
Age in years Mean (range)
Overall 37.8 (18–85) 38.9 (18–86) 38.7 (18–85) 38.5 (18–86)
Female 37.0 (18–81) 38.0 (18–86) 38.0 (18–85) 37.7 (18–86)
Male 38.6 (19–85) 39.8 (18–85) 39.6 (18–82) 39.3 (18–85)
HIV-uninfected 41.4 (18–85) 40.5 (18–83) 43.2 (20–79) 41.8 (18–85)
HIV-infected 36.5 (18–79) 37.6 (18–76) 37.6 (18–77) 37.3 (18–79)
HIV unknown 39.8 (18–85) 42.3 (18–86) 42.4 (18–85) 41.2 (18–86)
HIV information (%)
HIV-uninfected 48 (6.2) 57 (6.3) 66 (7.4) 0.33 171 (6.7)
HIV-infected 481 (62.3) 643 (71.4) 710 (79.3) ,0.0001 1834 (71.4)
HIV unknown 243 (31.5) 200 (22.2) 119 (13.3) ,0.0001 562 (21.9)
Extrapolated uninfected 70 (9.1) 73 (8.1) 76 (8.5) 0.70 219 (8.5)
Extrapolated infected 702 (90.9) 827 (91.9) 819 (91.5) 2348 (91.5)
Gender (%)
Female 387 (50.1) 491 (54.6) 510 (57.0) 0.005 1388 (54.1)
Male 381 (49.4) 406 (45.1) 384 (42.9) 0.009 1171 (45.6)
Unknown 4 (0.5) 3 (0.3) 1 (0.1) 0.14 8 (0.3)
Range of
1CD4+ cell count in HIV-infected (%)
Patients with information 125 405 493 1023
0–100 60 (48.0) 224 (55.3) 297 (60.2) 0.01 581 (56.8)
101–200 35 (28.0) 86 (21.2) 118 (23.9) 0.75 239 (23.4)
201–350 14 (11.2) 64 (15.8) 49 (9.9) 0.14 127 (12.4)
.350 16 (12.8) 31 (7.7) 29 (5.9) 0.01 76 (7.4)
Laboratory-confirmed cases of IPD admitted at Chris Hani Baragwanath Hospital, Soweto, South Africa, during 2003-2008. A total of 2,567 cases ranging from 18 to 86
years old were included in the study.
p values were obtained from a chi-square test for trend.
1CD4+ cell count obtained within 3 months before or after hospitalization.
doi:10.1371/journal.pone.0027929.t001
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2,005 cases (78.1%), including 529 (68.5%) in the early-HAART
era, 700 (77.8%) in the intermediate-HAART era and 776 (86.7%)
in the established-HAART era; p,0.0001. Gender data was
missing in 8 cases (0.3%), which were excluded from the gender-
specific analysis.
The most common clinical syndromes associated with IPD were
pneumococcal pneumonia (63.5%, pneumococci identified from
pleural fluid or blood in individuals with a physician-based
diagnosis of pneumonia), pneumococcal meningitis (21.2%),
pneumococcal bacteraemia without focus (14.1%, pneumococci
identified from blood without any localizing illness) and other IPD
(1.3%, pneumococci identified from sterile sites other than blood
or CSF in the absence of clinical or laboratory diagnosis of
meningitis or pneumonia).
The proportion of IPD cases involving women increased from
50.1% in the early-HAART to 57.0% in the established-HAART
era (p=0.005), which was especially apparent in the 25–44 year
age-group (48.3% vs. 56.9%, respectively; p=0.004). The
prevalence of HIV-infection was greater in women (1,033
[93.7%] of 1,102) than men (799 [88.8%] of 900; p=0.0001)
among tested individuals. Females were younger (37.7612.1 years)
than males (39.3610.9 years; p=0.004). HIV-infected patients
were younger (37.369.8 years) than HIV-uninfected patients
(41.8615.7 years; p,0.0001), (Table 1). Patients with unknown
HIV status compared to individuals with known HIV status were
older (41.2 years vs. 37.7 years, respectively; p,0.0001) but were
similar in gender status (51.3% vs. 55.0% female, respectively;
p=0.12).
CD4+ cell counts obtained within 3 months of the IPD episode
were available in 55.8% (1,023/1,834) of confirmed HIV-infected
cases and more commonly available in the established- (69.4%)
and intermediate- (63.0%) compared to the early-HAART era
(26.0%; p,0.0001). HIV-infected adults with CD4+ cell count
results were more likely to be categorized as having severe
immunosuppression (CD4+ cell count #100 cells per microliter) in
the established- (60.2%) and intermediate- (55.3%) than in the
early-HAART era (48.0%; p=0.01) (Table 1). Conversely, a lower
proportion of adults with IPD had CD4+ cell counts .350 cells
per microliter in the established-HAART era (5.9%) compared to
the early-HAART era (12.8%; p=0.01) (Table 1).
Incidence of culture-confirmed invasive pneumococcal
disease
There was no change in the overall incidence (per 100,000
population) of IPD comparing the early- (52.3) to the established-
HAART era (57.7; p=0.05) (Table 2). However, a 46.4% increase
was observed in incidence of pneumococcal meningitis (9.4 vs.
13.8, respectively; p=0.0004), whereas the incidence of non-
meningitis cases remained stable (42.9 vs. 43.9; p=0.68)
comparing the early to the established-HAART era, respectively.
The overall incidence of IPD, pneumococcal meningitis and
non-meningitis pneumococcal disease remained unchanged in
HIV-uninfected adults across the three time periods (Table 2).
Among HIV-infected adults, overall incidence of IPD did not
change comparing the early- (207.5) to the established-HAART
era (214.0; p=0.55). However, when stratifying by diagnosis there
was a 47.9% increase in incidence of pneumococcal meningitis
Table 2. Incidence of overall invasive pneumococcal disease and by syndrome for the three study periods in adults aged $18
years.
Incidence of IPD, cases per 100,000 population Change in incidence
Early-HAART; (N=) Intermediate-HAART; (N=) Established –HAART; (N=)
IRR (Established vs. Early);
[95% CI] p=
1
All population
Overall IPD 52.3 ; (772) 59.4 ; (900) 57.7 ; (895) 1.10 ; [1.00 ; 1.21] 0.05
Meningitis 9.4 ; (139) 12.6 ; (191) 13.8 ; (214) 1.46 ; [1.18 ; 1.81] 0.0004
Non-Meningitis 42.9 ; (633) 46.8 ; (709) 43.9 ; (681) 1.02 ; [0.92 ; 0.14] 0.68
Male 50.1 ; (381) 52.2 ; (406) 48.3 ; (384) 0.97 ; [0.84 ; 1.11] 0.63
Female 54.2 ; (387) 66.7 ; (491) 67.3 ; (510) 1.24 ; [1.09 ; 1.42] 0.001
HIV-infected adults
Overall IPD 207.5 ; (702) 225.6 ; (827) 214.0 ; (819) 1.03 ; [0.93 ; 1.14] 0.55
Meningitis 34.3 ; (116) 48.3 ; (177) 50.7 ; (194) 1.48 ; [1.17 ; 1.86] 0.001
Non-Meningitis 172.9 ; (585) 177.3 ; (650) 163.3 ; (625) 0.94 ; [0.84 ; 1.06] 0.32
Male 200.6 ; (339) 197.7 ; (360) 180.6 ; (341) 0.90 ; [0.77 ; 1.05] 0.17
Female 212.1 ; (359) 252.1 ; (465) 246.2 ; (477) 1.16 ; [1.01 ; 1.33] 0.03
HIV-uninfected adults
Overall IPD 6.2 ; (70) 6.4 ; (73) 6.5 ; (76) 1.06 ; [0.76 ; 1.46] 0.74
Meningitis 2.0 ; (23) 1.2 ; (14) 1.7 ; (20) 0.85 ; [0.46 ; 1.54] 0.58
Non-Meningitis 4.2 ; (48) 5.1 ; (59) 4.8 ; (56) 1.13 ; [0.77 ; 1.67] 0.52
Male 7.1 ; (42) 7.7 ; (46) 7.1 ; (43) 1.0 ; [0.65 ; 1.53] 0.99
Female 5.1 ; (28) 4.7 ; (47) 5.9 ; (33) 1.14 ; [0.69 ; 1.89] 0.61
Incidence risk ratios and percentage of change in incidence of disease between the early- and established-HAART eras, assuming that the prevalence of HIV infection in
untested cases is the same as in the tested cases.
1Chi-square test or Fischer-test.
IRR: incidence risk ratios established- vs. early-HAART era.
doi:10.1371/journal.pone.0027929.t002
High IPD Burden in the HAART Era
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27929between the early- (34.3) compared to the established–HAART
era (50.7; p=0.001), whereas the incidence of non-meningitis
disease remained the same between the early- and established–
HAART era (172.9 vs. 163.3, respectively; p=0.32), (Table 2).
The risk of IPD was 33.7-fold (95% CI: 26.4; 43.1) greater in HIV-
infected than in HIV-uninfected adults during the early-HAART
era and this increased risk persisted (IRR: 32.9; 95% CI: 26.0;
41.7) in the established-HAART era.
Stratification by gender revealed a 16.1% increase in incidence
of IPD in HIV-infected females from the early-HAART era
(212.1) compared to the established-HAART era (246.2; p=0.03),
whilst the incidence of IPD remained stable in HIV-infected males
(Table 2). The increase in incidence of IPD in HIV-infected
females was mainly due to an 18.7% increase in the 25–44 years
age-group (204.2 vs. 242.4; p=0.04) (Table S1). In addition, HIV-
infected females had 1.4 (95% CI: 1.2; 1.6) greater risk of IPD than
HIV-infected males in the established-HAART era; p,0.0001.
Although a decrease in incidence of IPD was observed in HIV-
infected individuals older than 65 years comparing the early
(3596.8) to established HAART-era (1565; p=0.04), these
individuals accounted for 1.3% and 1.8% of all IPD cases in the
respective periods. A detailed analysis of the incidence of IPD
stratified by age-group, HIV status and gender is reported in
online Table S1.
The analysis considering only individuals tested for HIV also
showed an overall increase in incidence (per 100,000) of IPD from
the early- (142.2) to established-HAART era (185.6; p,0.0001) in
HIV-infected adults (Table 3). The incidence of IPD, however,
remained unchanged from the early- (4.2) compared to estab-
lished-HAART era (5.6) in HIV-uninfected adults based on
confirmed HIV-seronegativity status of cases. Significant increase
in IPD, based on confirmed HIV-seropositivity of cases, from the
early- to established-HAART era was observed in adults in the 25-
44 age-group strata (142.7 vs. 181.8, p=0.0005) and a similar
trend was observed in the 18-24 years age-group strata (66.3 vs.
97.3; p=0.07) (Table 3) Although there were similar trends in
increase in incidence of IPD among the HIV-uninfected group,
based on documented HIV-seronegativity of cases, these were not
significant and the incidence of IPD remained less than 8 cases per
100,000 overall and in all age-groups across all study periods
(Table 3).
From the early- to the established-HAART era, the percentage
of cases detected on blood samples by latex agglutination/PCR
increased from 27.2% to 43.2% of the total cases, respectively;
p,0.0001. Since this change in laboratory procedures could have
influenced our results we recalculated the incidence of pneumo-
coccal meningitis in adults including only episodes with culture of
pneumococcus from CSF (Table 4). Incidence of CSF-culture-
confirmed pneumococcal meningitis increased by 42.5% from
33.7 in the early-HAART to 48.0 in the established-HAART era
in HIV-infected females (p=0.03).
Disease outcome
IPD clinical outcome data was unknown or missing in 366 cases
(14.3%). The in-hospital case fatality ratio (CFR) did not change
during the study period (30.2% in the early-HAART era, 34.1% in
the intermediate-HAART era and 31.6% in the established-
HAART era; p=0.66). The overall CFR was similar in HIV-
infected (29.2%) and HIV-uninfected persons (29.4%; p=0.95)
(Table 5). Among HIV-infected patients, those with meningitis
had a higher CFR (55.2%) compared to those with a non-
meningitis diagnosis (22.4%, p,0.0001) (Table 5). Similarly HIV-
uninfected individuals with meningitis had a higher CFR (43.9%)
compared with non-meningitis patients (24.1%; p=0.02). A
higher CFR was, however, observed in adults with non-meningitis
pneumococcal disease in whom HIV infection status was not
established (39.3%) compared to those with known HIV infection
status (22.5%; p,0.0001).
Table 3. Incidence of invasive pneumococcal disease across the three periods, limited to adults with known HIV-infection status.
Incidence of IPD, cases per 100,000 population Change in incidence
Early-HAART ; (N=) Intermediate-HAART ; (N=) Established –HAART; (N=)
IRR (Established vs.
Early); [95% CI] p=
1
Overall
Tested HIV-infected 142.2 ; (481) 175.4 ; (643) 185.6 ; (710) 1.31 ; [1.16 ; 1.47] ,0.000
Tested HIV-uninfected 4.2 ; (48) 5.0 ; (57) 5.6 ; (66) 1.34 ; [0.92 ; 1.94] 0.12
18-24 years old
Tested HIV-infected 66.3 ; (38) 76.2 ; (41) 97.3 ; (50) 1.47 ; [0.96 ; 2.23] 0.07
Tested HIV-uninfected 3.2 ; (8) 4.7 ; (11) 4.8 ; (11) 1.47 ; [0.59 ; 3.67] 0.40
25-44 years old
Tested HIV-infected 142.7 ; (346) 172.9 ; (459) 181.8 ; (504) 1.27 ; [1.11 ; 1.46] 0.0005
Tested HIV-uninfected 3.4 ; (18) 5.3 ; (28) 4.9 ; (26) 1.44 ; [0.79 ; 2.62] 0.24
45-64 years old
Tested HIV-infected 247.9 ; (95) 284.7 ; (133) 279.3 ; (148) 1.13 ; [0.87 ; 1.46] 0.36
Tested HIV-uninfected 6.5 ; (18) 3.8 ; (11) 7.0 ; (21) 1.07 ; [0.57 ; 2.00] 0.84
.=65 years old
Tested HIV-infected 799.3 ; (2) 1,927.6 ; (10) 834.9 ; (8) 1.05 ; [0.22 ; 4.88] 1.00
Tested HIV-uninfected 4.5 ; (4) 7.2 ; (7) 7.4 ; (8) 1.64 ; [0.49 ; 5.45] 0.57
Incidence risk ratios and percentage of change in incidence of disease between the early- and established-HAART eras.
1Chi-square test or Fischer-test.
IRR: incidence risk ratios established- vs. early-HAART era.
doi:10.1371/journal.pone.0027929.t003
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Incidence of IPD, cases per 100,000 population Change in incidence
Early-HAART; (N=) Intermediate-HAART; (N=) Established –HAART; (N=)
IRR (Established vs. Early);
[95% CI] p=
1
All population
Overall 8.6 ; (127) 10.9 ; (165) 10.1 ; (156) 0.86 ; [0.68 ; 1.08] 0.19
Male 8.0 ; (61) 9.1 ; (71) 7.4 ; (59) 1.08 ; [0.75 ; 1.54] 0.68
Female 9.0 ; (64) 12.8 ; (94) 12.8 ; (97) 0.70 ; [0.51 ; 0.96] 0.03
HIV-infected adults
All population 30.7 ; (104) 41.7 ; (153) 36.9 ; (141) 0.83 ; [0.65 ; 1.07] 0.16
Male 26.6 ; (45) 35.7 ; (65) 25.4 ; (48) 1.05 ; [0.70 ; 1.57] 0.82
Female 33.7 ; (57) 47.7 ; (88) 48.0 ; (93) 0.70 ; [0.50 ; 0.98] 0.03
HIV-uninfected adults
All population 2.0 ; (23) 1.0 ; (12) 1.3 ; (15) 1.58 ; [0.82 ; 3.02] 0.17
Male 2.7 ; (16) 1.0 ; (6) 1.8 ; (11) 1.49 ; [0.69 ; 3.21] 0.31
Female 1.3 ; (7) 1.1 ; (6) 0.7 ; (4) 1.81 ; [0.53 ; 6.18] 0.34
Incidence risk ratios and percentage of change in incidence of disease between the early- and established-HAART eras, assuming that the prevalence of HIV infection in
untested cases is the same as in the tested cases.
1Chi-square test or Fischer-test.
IRR: incidence risk ratios established- vs. early-HAART era.
95% CI: 95% confidence interval.
HAART: highly active anti-retroviral treatment.
doi:10.1371/journal.pone.0027929.t004
Table 5. Case fatality ratios and incidence of mortality during the three study periods in IPD patients by HIV status and diagnosis.
Early-HAART era Intermediate-HAART era Established -HAART era p=
6-year period
(2003-2008)
Cases with known outcome (%) 616 (79.8) 772 (85.8) 813 (90.8) ,0.0001 2,201 (85.7)
Died during hospitalization (%)
Overall 186 (30.2) 263 (34.1) 257 (31.6) 0.66 706 (32.1)
Tested HIV-infected 109 (26.3) 176 (30.6) 199 (29.8) 0.28 484 (29.2)
Tested HIV-uninfected 9 (22.0) 19 (40.4) 17 (26.2) 0.84 45 (29.4)
HIV unknown 68 (42.2) 68 (45.6) 41 (51.3) 0.19 177 (45.4)
Meningitis HIV-infected 35 (56.5) 70 (58.3) 85 (52.5) 0.45 190 (55.2)
Meningitis HIV-uninfected 5 (38.5) 6 (60.0) 7 (38.9) 0.94 18 (43.9)
Meningitis HIV unknown 25 (65.8) 25 (55.6) 15 (68.2) 0.98 65 (61.9)
Non-meningitis HIV-infected 74 (21.0) 106 (23.2) 114 (22.5) 0.65 294 (22.4)
Non-meningitis HIV-uninfected 4 (14.3) 13 (35.1) 10 (21.3) 0.70 27 (24.1)
Non-meningitis HIV unknown 43 (35.0) 43 (41.3) 26 (44.8) 0.18 112 (39.3)
Incidence of mortality (per 100,000)
Overall 12.6 17.4 16.6 0.006
Tested HIV-infected 32.2 48.0 52.0 0.0001
Tested HIV-uninfected 0.8 1.7 1.5 0.17
Meningitis HIV-infected 10.3 19.1 22.2 0.0001
Meningitis HIV-uninfected 0.44 0.52 0.60 0.60
Non-meningitis HIV-infected 21.9 28.9 29.8 0.04
Non-meningitis HIV-uninfected 0.35 1.1 0.86 0.18
p values were obtained from a chi-square test for trend.
doi:10.1371/journal.pone.0027929.t005
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microliter had a higher CFR compared to those with CD4+ cell
counts.100cellspermicroliterformeningitiscases(57.8%[63/109]
vs. 38.8% [31/80], respectively; p=0.01) as well as for non-
meningitis cases (29.4% [124/422] vs. 9.8% [32/328], p,0.0001).
Overall, a higher CFR was observed in HIV-infected adults with
CD4+ cell counts #100 cells per microliter (35.2%; [186/529]) than
those with CD4+ cell counts .100 cells per microliter (15.5%; [63/
406]) (adjusted IRR for disease syndrome 2.3 [95% CI: 1.7; 3.0];
p,0.0001).Nodifference in CFR was observed between females and
males after adjusting for CD4+ cell counts and disease syndrome.
The overall incidence of IPD-associated mortality (per 100,000)
increased, based on documented HIV infection status of cases, in
HIV-infected adults from the early- (32.2) compared to estab-
lished-HAART (52.0; p=0.0001) period. Similarly, increases in
mortality incidence were observed for meningitis (10.3 vs. 22.2;
p=0.0001) and non-meningitis (21.9 vs. 29.8; p=0.04) in
confirmed HIV-infected adults. The mortality rates did not
change significantly in HIV-uninfected individuals, based on
confirmed HIV-negative cases, (Table 5).
HAART effectiveness
During 2008, 40% of AIDS patients (defined by CD4+ cell
count less than 200 cells per microliter or WHO stage 4) were
estimated to be on HAART in South Africa. [14] During 2008,
230 IPD HIV-infected patients had CD4+ cell counts #200 cell
per microliter being eligible for HAART according to the national
guidelines. [19] HAART information was available on 192 of
these IPD cases from 2008 (175 cases not on HAART and 17 cases
on HAART). Consequently the frequency of IPD cases that
occurred in the HAART treated group was 8.9%. Using the
screening method [24] and based on estimates of HAART
coverage and our study findings, HAART was 85.5% effective in
reducing IPD in HIV-infected adults.
Discussion
Unlike reports from developed countries [6,7] and a recent
study from Malawi [9] our study failed to show any impact of the
antiretroviral treatment program on the burden of IPD in HIV-
infected adults. This result was largely attributed to an increase in
IPD incidence observed in HIV-infected women, especially
women aged 25–44 years. In addition to the majority (71.4%) of
IPD cases occurring in adults confirmed to be HIV-infected, the
risk of IPD remained consistently 33- to 34-fold greater in HIV-
infected compared to -uninfected adults over the study period. The
baseline estimate of IPD, i.e. in the early-HAART era, observed in
our study was similar to previous reports from the same study
population in 1997 when HAART was not being used. The
incidence of IPD in adults in this population in the latter study was
45 cases per 100,000 in the 25–44 years old, 42 cases per 100,000
in the 45–64 years old and 50 cases per 100,000 in adults older
than 65 years. [16]
The high burden of IPD in the study population, attributed to
the HIV epidemic, is further emphasized by the increase in overall
and HIV-confirmed incidence of IPD-associated mortality rates in
adults. Case fatality ratios of IPD among HIV-infected patients
vary widely according to the population studied. Several studies
that compare mortality between HIV-infected (9%–21%) and
HIV-uninfected (3%–15%) individuals observed no significant
differences in mortality in the two populations [8,15,16] and even
the degree of CD4+ cell depletion did not influence mortality rates
in IPD. [25] HIV-infected adults in our study with CD4+ cell
counts #100 cells per microliter, however, had a higher in hospital
CFR (35%), after adjusting for disease syndrome, compared to
those with CD4+ cell counts .100 cells per microliter.
A similar analysis on the trends of IPD incidence in South
African children and teenagers revealed that up-scaling of the
HAART program in HIV-infected children was associated with a
50.8% reduction in IPD hospitalization and 65.2% reduction in
IPD-associated mortality rates in the same population. [26]
Reductions were evident for both pneumococcal meningitis and
pneumococcal non-meningitis disease. [26] This suggests that the
HAART program among children has been more successful in its
implementation and management in this community compared to
its scale and coverage in adults.
Using the incidence of IPD as a proxy measure of the
effectiveness of the HAART program in reducing opportunistic-
infections at a population level in HIV-infected adults, our study
indicates an ongoing high prevalence of immunosupression in this
community. Nevertheless we used the screening method to
estimate the likely effectiveness of HAART based on the
prevalence of HAART coverage in HIV-infected cases. [24] This
method relies on external standardization and depends on the
accuracy of the external estimates used. We used a conservative
estimate of HAART coverage derived from a study by Adam et
al., where combined CD4+ cell count and clinical criteria were
used to define HAART eligibility. [18] Other sources, specifically
the ASSA2003 model, [14] commonly used in extrapolating
HAART targets in South Africa assume patients in need in terms
of WHO clinical staging only, produced higher estimates of
coverage. We estimated that even though adults on HAART are
at reduced risk of IPD, an effect was not detected at the population
level. These seemingly contradictory findings might be the result of
number of factors, including: i) over-estimates of HAART
coverage in the population; ii) a maturation in the HIV epidemic,
including a larger population with progression to severe
immunosupression; iii) possible inadequacies in the HAART
program with regard to patient management and compliance; and
iv) delay in accessing of HAART treatment by severely
immunocompromized HIV-infected individuals.
A limitation of applying the screening method in evaluating the
effectiveness of HAART in our study, however, include that acute
infections such as the IPD may have caused a transient reduction
in CD4+ counts. Hence, the proportion of IPD cases who
purportedly qualified for HAART may have been over-estimated.
A small cohort study in HIV-infected adults, in a poor inner city
population in Baltimore (USA) between 1990 to 2003 also did not
observe any change in incidence of IPD despite widespread
implementation of HAART. [27] In addition, another USA study
involving nation-wide hospitalization trends of IPD among HIV-
infected subjects, whilst observing a marked decrease in the rate of
IPD hospitalizations from 1994 to 2005, after adjusting for age, sex
and payer the decline was only apparent after introduction of
childhood PCV vaccination and more likely to have been
attributable to indirect protection conferred by the childhood
PCV immunization program. [28]
Although an analysis from Malawi reported that increase use of
antiretroviral was associated with a decline in IPD, the results were
confounded by changes in the method of surveillance of IPD prior
to and after the establishment of the HAART program. [9] In
addition the lack of population denominators and HIV specific
data, limited the scope of the analysis in attributing the reduction
in IPD cases to the HAART program. [9]
Our study has potential limitations, including those which are
inherent to any longitudinal observational/time-series analysis.
These include the possibility of changes in practice in both clinical
practice, as well as surveillance systems over time. Improvements
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our study included an increase in the proportion of cases in whom
outcome, HIV-infection and CD4+ cell counts data were
available. In the early-HAART era HIV was possible under-
diagnosed and consequently may have falsely lead to over-estimate
of IPD in HIV-uninfected and under-estimate in HIV-infected
subjects during that period.
Although changes in clinical practices by attending physicians
(i.e. likelihood of performing blood cultures) may had also
influence our observations, a measure of IPD which is least
subject to changes in patient-management is microbiologically
confirmed meningitis. The increase in incidence in pneumococcal-
meningitis and especially in meningitis culture confirmed on CSF
from the early- compared to the established-HAART era in HIV-
infected adults, whilst remaining unchanged in HIV-uninfected
adults, corroborates our findings of an overall increase in IPD in
HIV-infected adults as being plausible.
The ongoing high burden of IPD in HIV-infected adults in our
study population indicates an urgent need for additional
approaches to prevent pneumococcal disease. Although expanding
and optimizing HAART therapy is likely to be most effective in
reducing the risk of opportunistic infections in these adults, other
strategies are needed. One such strategy, which is recommended
by WHO and included in the South African HIV/AIDS
treatment guidelines, is cotrimoxazole prophylaxis. [29] Cotri-
moxazole has been shown to reduce the burden of bacterial
infections in African HIV-infected adults, albeit not specifically
confirmed pneumococcal disease. [30,31] Of concern, however,
has been the increase in prevalence of antibiotic non-susceptible
pneumococcal strains involving nasopharyngeal colonization and
IPD in HIV-infected subjects on prophylaxis. [32,33]
A different strategy of decreasing the burden of IPD in HIV-
infected adults includes the possibility of vaccination against
pneumococcal disease. The use of PPV23 in African HIV-infected
adults is controversial, based on a Ugandan study which showed an
increase in pneumonia in the short-term period following PPV23
vaccination of HIV-infected adults not on HAART [34] albeit
subsequently showing a 16% reduction in all-cause mortality. [35]
The lack of PPV23 efficacy against pneumonia observed in the study
by French et al. probably relates to their cohort of PPV23 vaccinees
mainly having high viral loads (.100,000 copies per millilitre), [34]
which has been established as an important factor for lack of PPV23
effectiveness even inthe USA. [36] Nevertheless, PPV23 vaccination
is not routinely undertaken in South African HIV-infected adults or
recommended by the WHO for African HIV-infected adults. More
recently a 7-valent PCV (PCV7) was established to be safe and
efficacious in preventing vaccine-serotype specific IPD in African
HIV-infected adults with previously documented history of IPD,
many (86%) of whom were not on HAART. [37]
Another possibility for reducing the burden of IPD, of at least
select serotypes included in PCVs formulations, in HIV-infected
and –uninfected adults is through indirect protection from
childhood PCV vaccination. This may be achieved by immuni-
zation of large proportions of young children in the community
with PCV. Experience from the USA indicated that widespread
immunization of young children with PCV7 was associated with a
69% reduction in vaccine-serotype IPD in select adult age groups,
including a 91% reduction in HIV-infected adults. [38,39] PCV7
was introduced in the South African public childhood immuni-
zation program in April 2009 and the effect thereof on protection
of HIV-infected adults is being studied.
There have as yet been no studies clearly demonstrating a
reduction in the incidence any opportunistic infections among
HIV-infected adults in the HAART era in SA. As HAART
coverage increases ongoing surveillance will clarify the situation.
However adjunctive policies appear to be warranted in the
prevention of IPD.
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